The most recent report from the U.S. Judicial Panel on Multidistrict Litigation shows 2,231 testosterone lawsuits included in the Illinois MDL —and there’s no sign that the flood of lawsuits will let up any time soon. According to the Public Access to Court Electronic Records (PACER) database, over 40 new testosterone lawsuits were filed in the last week alone. A testosterone lawsuit filed last month by a ...
Testosterone Therapy Lawsuits Not Letting Up as South Carolina Claim Joins MDL
Posted September 15, 2015 in Product News and Recalls | Testosterone Therapy
New Testosterone Study Shows Mixed Results
Posted September 6, 2015 in Product News and Recalls | Testosterone Therapy
Another pharma-funded testosterone therapy study has been published, this time in the Journal of the American Medical Association. The authors, two of whom worked with or profited from big-name testosterone therapy manufacturers, found that men who took testosterone did not show any significant difference in risk of atherosclerosis; at the same time, the study also revealed these men experienced no sexual or health-related improvement in quality of life. As noted by ...
FDA Not Convinced about Testosterone Therapy Safety
Posted August 27, 2015 in Product News and Recalls | Testosterone Therapy
The U.S. Food and Drug Administration (FDA) recently informed “Low-T” drug manufacturers they will need to do a better job of demonstrating their products’ safety if they wish to market them to aging men. The agency’s argument was laid out by Christine P. Nguyen, a Deputy Director for Safety at the FDA, in an article in the New England Journal of Medicine.
Earlier this year, the ...
continue reading...New Study Unable to Show Testosterone Does Not Increase CV Risk
Posted August 16, 2015 in Product News and Recalls | Testosterone Therapy
A new study published in the Mayo Clinic Proceedings purports to show that testosterone therapy does not increase the risk of deep vein thrombosis (DVT) or pulmonary embolism (PE), though the validity of these results may be questionable.
Testosterone therapy products are intended to regulate hormone levels in men with medically confirmed low testosterone. (The drugs are not approved for use in men experiencing the natural ...
continue reading...AbbVie Profits Rise 4.3% as Testosterone Lawsuits Mount
Posted June 1, 2015 in Product News and Recalls | Testosterone Therapy
Pharmaceutical giant AbbVie, Inc. has reported a 4.3 percent increase in its first-quarter profits, according to Nasdaq. The Chicago-based company cited heightened sales of anti-inflammatory medications, and detailed its plans to keep its top-selling drug Humira afloat.
Despite the rise in profits, AbbVie still faces financial trouble in the form of testosterone lawsuits. The company’s popular “low-T” product, AndroGel, is one of a handful or prescription testosterone ...
continue reading...Health Experts Accuse “Low-T” Drug Manufacturers of “Disease Mongering”
Posted May 26, 2015 in Drug and Medical Device Lawsuits | Product News and Recalls | Testosterone Therapy
A recent Forbes article explores the prevalence of “Low-T” drug ads by companies like AbbVie and Eli Lilly & Co., and how two men’s health experts think the advertisements should be banned.
Testosterone therapy products have been associated with an increased risk of serious cardiovascular health effects. A study published in November 2013 linked testosterone therapy to increased rates of heart attack, stroke, and ...
continue reading...
